MIRA
INFORM REPORT
|
Report Date : |
16.03.2007 |
IDENTIFICATION
DETAILS
|
Name : |
FOUR A PHARMA FOR
PHARMACEUTICAL INDUSTRIES SAE |
|
|
|
|
Registered Office : |
4 Bourj Al
Hussain Moharam Darwish Street, Faisal, Giza, Cairo |
|
|
|
|
Country : |
Egypt |
|
|
|
|
Financials (as on) : |
31.12.2005 |
|
|
|
|
Date of Incorporation : |
2001 |
|
|
|
|
Com. Reg. No.: |
7840, Giza |
|
|
|
|
Legal Form : |
Egyptian Joint Stock Company |
|
|
|
|
Line of Business : |
Engaged in the manufacture
of pharmaceutical preparations and medicines. |
RATING &
COMMENTS
|
MIRA’s Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
US$ 300,000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
Regular |
|
|
|
|
Litigation : |
Clear |
SUMMARY
Company Name : FOUR A PHARMA FOR PHARMACEUTICAL INDUSTRIES SAE
Country of Origin : Egypt
Legal Form : Egyptian Joint Stock Company
Registration Date : 2001
Commercial Registration Number : 7840, Giza
Issued Capital : £E 5,000,000
Paid up Capital : £E 5,000,000
Total Workforce : 75
Line of Business : Manufacturers of pharmaceutical preparations and medicines.
Financial Condition : Fair
Payments : Nothing detrimental uncovered
Operating Trend : Steady
COMPANY NAME
FOUR A PHARMA FOR
PHARMACEUTICAL INDUSTRIES SAE
ADDRESS
Registered & Physical Address
Street : 4 Bourj Al Hussain Moharam
Darwish Street
Area : Faisal, Giza
Town : Cairo
Country : Egypt
Telephone : (20-2) 7238153 / 7238154
Facsimile : (20-2) 7238152
Email : info@fourapharma.com
Premises
Subject operates
from a small suite of offices that are rented and located in the Central
Business Area of Cairo.
Branch Office (s)
Location Description
·
Plot No. 8 Factory
premises
3rd Industrial Area
6th of October City
KEY PRINCIPALS
·
Ali Abdul Fattah Ali Chairman
·
Mohamed Abdul Fattah Ali Director
·
Nagwa Saeed Mostafa Director
·
Attar Ezzat General
Manager
·
Dr Jamal Mostafa Research
& Development Manager
·
Dr Thamer Samir Technical
Manager
·
Asim Salem Export
Manager
LEGAL FORM &
OWNERS
Date of Establishment : 2001
Legal Form :
Societe Anonyme Egyptienne -
SAE (Egyptian Joint Stock
Company)
Commercial Reg. No. : 7840, Giza
Issued Capital : £E 5,000,000
Paid up Capital : £E 5,000,000
Name of Shareholder
(s)
·
Ali Abdul Fattah Ali
·
Mohamed Abdul Fattah Ali
·
Nagwa Saeed Mostafa
·
Local businessmen and private investors
Note to the Legal Form
The Egyptian Company Law provides that the capital of a Societe Anonyme Egyptienne - SAE – should not be less than £E 500,000 if shares are offered to the public and £E 250,000 if not. If shares are offered to the public they are freely transferable, if not, transfer may be restricted. Liability of shareholders is limited.
LINE OF BUSINESS
Operations : Engaged in the manufacture of
pharmaceutical preparations and medicines.
Import Countries
: Europe and the Far East.
Operating Trend
: Steady
Subject has a
workforce of 75 employees.
FINANCIAL HIGHLIGHTS
Financial
highlights provided by outside sources are given below :
Currency : Egyptian
Pound (£E)
Year
Ending 31/12/04 : Year
Ending 31/12/05 :
Total Revenue £E 17,500,000 £E 18,900,000
Local sources
consider subject’s financial condition to be Fair.
BANKERS
·
National
Societe Generale Bank
5 Champollion Street
Cairo
Tel : (20-2) 7707777
Fax
: (20-2) 7707799
PAYMENT HISTORY
No complaints
regarding subject’s payments have been reported.
GENERAL COMMENTS
Opinion on the
credit figure of US$ 150,000:
Established in
2001, subject is involved in the manufacture of pharmaceutical preparations and
medicines.
Local sources report that payment obligations are met in a generally
timely manner and the operating history is clear. As such the company is deemed
a fair trade risk and the above credit figure is considered to be within
subject’s financial means.
Maximum suggested
credit figure: US$ 300,000
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average/normal. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)